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Abstract
Background: Musculoskeletal manifestations of the human immunodeficiency virus (HIV) have been described
since the outset of the global HIV epidemic. Articular syndromes that have been described in association with HIV
include HIV-associated arthropathy, seronegative spondyloarthropathies (SPA) (reactive arthritis, psoriatic arthritis
(PsA) and undifferentiated SPA), rheumatoid arthritis (RA) and painful articular syndrome.
Methods: We carried out a computer-assisted search of PubMed for the medical literature from January 1981 to
January 2015 using the keywords HIV, acquired immune-deficiency syndrome, rheumatic manifestations, arthritis,
spondyloarthropathy, anti-TNF and disease modifying antirheumatic drugs. Only English language literature was
included and only studies involving adult human subjects were assessed.
Results: There are challenges in the management of inflammatory arthritis in patients who are HIV-positive, including
difficulties in the assessment of disease activity and limited information on the safety of immunosuppressive drugs in
these individuals.
Conclusions: This review focuses on the clinical characteristics of the inflammatory articular syndromes that have been
described in association with HIV infection and discusses the therapeutic options for these patients.
Keywords: HIV, Acquired immune-deficiency syndrome, Rheumatic manifestations, Arthritis, Spondyloarthropathy,
anti-TNF and Disease modifying antirheumatic drugs
Background
Musculoskeletal manifestations of the human immuno-
deficiency virus (HIV) have been described since the
outset of the global HIV epidemic. The first reports of
rheumatological symptoms of the infection occurred
3 years after its discovery, with Winchester et al. describ-
ing a case of reactive arthritis in a patient with advanced
acquired immunodeficiency syndrome (AIDS) [1]. Sub-
stantial gains have been made at stemming the spread of
HIV, with the rate of new cases each year steadily declin-
ing and the number of AIDS-related deaths also falling
from 3.1 million in 2005 to 1.7 million in 2012 [2]. HIV
positive patients are also living longer due to antiretro-
viral (ARV) therapy and as a result, chronic non-
communicable diseases in long-term sufferers of HIV
are now emerging as a significant cause of morbidity.
Patients infected with HIV have been shown to have a
higher risk of developing rheumatic diseases [3], and this
can occur at any stage of the disease. Moreover, HIV
positive patients having musculoskeletal involvement
have reduced quality of life, when compared to those
without rheumatic symptoms [4]. Articular syndromes
that have been described in association with HIV include
HIV-associated arthropathy, seronegative spondyloar-
thropathies (SPA) (reactive arthritis, psoriatic arthritis
(PsA) and undifferentiated SPA), rheumatoid arthritis
(RA) and painful articular syndrome. Other nonarticular
rheumatological conditions including osteonecrosis, vas-
culitis and myositis are well described manifestations of
HIV but are not within the scope of this article. This re-
view focuses on the clinical characteristics of the inflam-
matory articular syndromes that have been described in
association with HIV infection and discusses the thera-
peutic options for these patients.* Correspondence: rjmoots@liv.ac.uk
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Methods
We carried out a computer-assisted search of PubMed and
google scholar for the medical literature from January 1981
to January 2015 using the keywords HIV, acquired
immune-deficiency syndrome, rheumatic manifestations,
arthritis, spondyloarthropathy, anti-TNF and disease modi-
fying antirheumatic drugs. Only English language literature
was included and only studies involving adult human sub-
jects were assessed (Fig. 1).
Results
HIV-associated Arthropathy
HIV-associated arthritis can occur at any stage of HIV
illness. It presents as an asymmetric oligo arthritis, sym-
metrical polyarthritis or as a monoarthritis. The asym-
metric, oligo arthritis variant is the most common form,
has a male preponderance, and predominately affects
the knees and ankles [5]. The symmetrical polyarthritis
variant closely mimics RA, with patients exhibiting simi-
lar deformities to rheumatoid patients, including ulnar
deviation. It is characterised however by greater acuity at
onset and is usually nonerosive. The presence of Jaccoud
arthropathy as part of an HIV-associated arthritis has
also been described occasionally [6]. HIV-associated
arthritis tends to be short lived with its peak intensity
occurring in 1 to 6 weeks [7]. However, some patients
develop a chronic destructive arthropathy, associated
with marked functional disability [8]. Features of mu-
cocutaneous involvement or enthesopathy are rare.
Radiological changes can occasionally mimic RA, with
joint space narrowing, erosions and periarticular
osteopenia [5]. However, some patients demonstrate
new bone formation - a radiological finding unusual
in RA [9]. There is an inflammatory, but sterile pat-
tern on synovial fluid analysis with white cell count
in the region of 50–2600 cells/μL, and normal glucose
[5]. ANA, Rheumatoid Factor and HLA B27 are nega-
tive [10]. There remains considerable debate as to
whether HIV infection is the cause of, or a coinciden-
tal finding in patients who are HIV positive and sero-
negative with an inflammatory arthritis. The evidence
supporting the hypothesis that HIV has a direct in-
flammatory effect on synovial tissue is twofold. Firstly,
p24 antigen, HIV DNA and tuboreticular inclusions
have been detected in the synovial fluid of affected
joints [11]. These all point to a viral aetiology. P24
antigen in particular has been found in joints at levels
ten times higher than the serum levels [11]. Secondly,
there is the epidemiological observation of increased
prevalence of rheumatic conditions in HIV positive
patients [5]. Some authors have speculated that the
true prevalence of HIV-associated arthritis is higher
than is generally recorded [11].
Painful articular syndrome
The painful articular syndrome is a self-limited disorder
of unknown aetiology, lasting for less than 24 h in pa-
tients with HIV infections. It is reported in up to 10 %
Fig. 1 Flowchart of study identification and selection
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of African HIV-seropositive patients [12] and is noted to
be more common in those with advanced infection [13].
Bone and joint pain is noted, especially in the lower ex-
tremities in an asymmetric pattern, which is out of pro-
portion to clinical findings. Though synovitis is absent,
pain is excruciating and debilitating leading to hospital
treatment in more than half of patients. The joints most
commonly involved are the knees, shoulders and elbows
[11]. Its prevalence appears to have reduced since the
advent of HAART [14].
Spondyloarthropathies
The emergence of HIV has changed the epidemiological
profile of rheumatic diseases particularly in sub-Saharan
Africa. The SPA were previously described as uncom-
mon in sub-Saharan African due to the rarity of the
HLA-B27 allele, but there is an increased prevalence of
PsA and reactive arthritis in Africa since the outset of
the HIV epidemic [15]. Severe forms of psoriasis and
PsA have been reported and are almost universally asso-
ciated with HIV [16]. This is in contrast to Caucasian
HIV positive patients where an increased severity but
not prevalence of psoriasis and arthritis is seen [14].
There has been a change in the presentation and severity
of these conditions since the widespread use of highly
active anti-retroviral therapy [8], with the prevalence of
PsA and reactive arthritis declining [14].
Reactive arthritis
A link between HIV and reactive arthritis has been reported
since the early stages of the HIV epidemic. The most typical
presentation is that of a seronegative peripheral oligo arth-
ritis predominantly involving the lower extremities, usually
accompanied by enthesitis [11]. Mucocutaneous features
are common - classically keratoderma blenorrhagicum and
circinate balanitis. Skin involvement can be so extensive as
to cause diagnostic confusion with PsA [11]. Urethritis oc-
curs in similar frequency to HIV-negative reactive arthritis.
Axial involvement and uveitis are uncommon, but do
occur. HLA-B27 is found in 80–90 % of Caucasians with
HIV-associated reactive arthritis, while studies of Africans
with HIV-associated reactive arthritis have found nearly all
to be HLA-B27-negative [7]. As in HIV uninfected patients,
antecedent history of genitourinary and gastrointestinal in-
fection is common. This point could hold the key to
explaining the geographical differences observed in the
prevalence of reactive arthritis – countries with higher rates
of HIV contracted through intravenous drug use for ex-
ample, rather than sexual contact, have observed lower
rates of reactive arthritis [7].
Psoriatic arthritis
Along with an increased occurrence, studies suggest that
HIV-infected patients with psoriasis have more severe
and persistent skin lesions with guttate, inverse and ery-
throdermic subtypes most common [17]. Similarly, those
with joint disease generally suffer a more severe, deform-
ing, erosive arthropathy refractory to conventional treat-
ment [15], with worse clinical features in advanced HIV
infection [13]. The onset of psoriatic arthritis in the set-
ting of HIV frequently heralds the development of
opportunistic infections [18]. The typical clinical presen-
tation is an asymmetrical oligo- or polyarthritis, with a
predilection for the lower limbs [16]. A symmetrical
polyarthritis is also described with arthritis mutilans, but
distal interphalangeal involvement and axial SPA pat-
terns appear less freqeuntly [16]. Onset may be abrupt,
with the development of erosions and disability within
weeks. In addition, the number of joints affected tends
to increase with time [19].
Undifferentiated spondyloarthropathy
Some HIV-infected patients fail to develop the entire
spectrum of clinical manifestations for disease to be
classified as ankylosing spondylitis, reactive arthritis, or
PsA, and are labelled as undifferentiated SPA. The pre-
dominant rheumatic manifestations exhibited in those
with undifferentiated SPA include achilles tendinitis,
dactylitis, low-back pain, plantar fasciitis, ankle pain and
shoulder pain [11]. Manifestations of keratoderma ble-
norrhagicum and circinate balanitis are common how-
ever a lower frequency of uveitis and axial skeleton
involvement is observed [20]. Psoriasiform skin rashes
are also common and can be extensive. On magnetic
resonance imaging and sonographic imaging, synovitis
of the knees, extensive polyenthesitis, and adjacent oste-
itis are the frequent findings [21].
Rheumatoid arthritis
The immune dysregulation inherent to HIV infection
may interfere with the diagnosis of RA or mimic its clin-
ical presentation. There have been reports of RA arising
de novo in HIV positive patients as part of immune re-
constitution syndrome following the initiation of anti
retroviral therapy [8]. As already stated, HIV-associated
arthritis can present as a polyarthritis of the small joints
that mimics RA clinically and radiographically. Sero-
logical markers of RA can be found in HIV infected pa-
tients, and visa versa. Du Toit et al. found positive IgG
RF and anti-CCP antibodies in 47 and 15 % of patients
with HIV/AIDS respectively, although most patients had
low titers [22]. In this study, the antibody titers reduced
after 6 months of antiretroviral therapy and no patients
developed RA at 1 year follow-up. Conversely, Li et al.
found false-positive HIV serology in 16 % of their cohort
of Chinese RA patients [23].
Several reports have suggested that patients with
established rheumatoid arthritis experience clinical
Adizie et al. BMC Infectious Diseases  (2016) 16:100 Page 3 of 7
Table 1 Summary of clinical characteristics of Inflammatory Articular Syndromes in HIV positive patients
Clinical characteristics
Syndrome HIV negative HIV Positive References
RA Symmetrical small joint polyarthritis,
hands and feet.
RA activity can improve with HIV
and flare or arise de novo
following HAART
-Reveille JD, Williams M. Rheumatologic
complications of HIV infection. Best Practice &
Research Clinical RheumatologyVol. 20, No. 6
-du Toit et alLack of specificity of anticyclic
citrullinated peptide antibodies in advanced
human immunodeficiency virus infection. J
Rheumatol 2011;38:1055–60
Positive Rheumatoid Factor and/or Anti-
CCP
HIV infection itself can be
associated with false positive
Rheumatoid Factor and CCP
Extra articular manifestations such as
interstitial lung disease and rheumatoid
nodules
HIV Arthropathy can mimic
rheumatoid clinically
ESR may remain persistently raised
despite good disease control
Reactive Arthritis Seronegative peripheral oligo arthritis
predominantly involving the lower
extremities, usually accompanied by
enthesitis. Keratoderma blenorrhagicum
and circinate balanitis.
Skin involvement can be more
florid than HIV –ve.
-Lawson E, Walker-Bone K. The changing
spectrum of rheumatic disease in HIV infection
Br Med Bull. 2012 Sep;103(1):203-21
Psoriaform rashes can be so
extensive as to cause diagnostic
confusion with PsA.
Axial involvement and uveitis are
less common than HIV –ve
HLA B27 commoner in Caucasians
than black Africans
Psoriatic Arthritis Varied presentation: Typical clinical phenotype is an
asymmetrical oligo- or
polyarthritis, with a predilection
for the lower limbs
Njobvu P, McGill P. Psoriatic arthritis and
human immunodeficiency virus infection in
Zambia. J Rheumatol 2000;27:1699–702Inflammatory joint pain/spinal pain
Distal interphalangeal joint swelling,
dactilytis, symmetrical polyarthritis,
spondylitis, enthesitis and arthritis
mutilans
Can present with an abrupt-onset
florid polyarthritis, particularly in
advanced HIV
History of Psoriasis or family history More severe and persistent skin
lesions with guttate, inverse and
erythrodermic subtypes compared
to HIV -ve
Distal interphalangeal involvement
and axial SPA patterns appear less
frequently compared to HIV -ve
Undifferentiated
Spondyloarthropathy
Clinical manifestations of ankylosing
spondylitis, reactive arthritis, or PsA
without full spectrum to be classified as
any syndrome
Achilles tendinitis, dactylitis, low-
back pain, plantar fasciitis, ankle
pain and shoulder pain most
commonly.
Mody G, Parke F. Articular manifestations of
human immunodeficiency virus infection. Best
Practice & Research Clinical RheumatologyVol.
17, No. 2, pp. 265–287, 2003
Painful articular
syndrome
N/A Severe bone and joint pain in the
lower extremities in an
asymmetric pattern.
Reveille JD. The changing spectrum of
rheumatic disease in human
immunodeficiency virus infection. Semin
Arthritis Rheum. 2000;30(3):147
No objective synovitis.
Can be debilitating
HIV Arthropathy N/A Presents as an asymmetric oligo
arthritis, symmetrical polyarthritis
or as a monoarthritis.
Plate A-M, Boyle B. Musculoskeletal Manifesta-
tions of HIV. AIDS Read. 2003;13(2)
Patients lack features of
mucocutaneous involvement or
enthesopathy
Symmetrical polyarthritis variant
closely mimics RA.
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improvement after the development of immunodefi-
ciency secondary to HIV [15] Recently, Tarr et al. ob-
served that most HIV positive RA patients in their
cohort had lower joint counts and composite disease
activity scores despite stopping methotrexate therapy
compared to HIV negative controls, supporting the sug-
gestion that HIV infection improves RA disease activity
[24]. Their study further highlighted difficulties in moni-
toring patients with inflammatory arthritis, who happen
to be HIV positive. A persistently elevated ESR is a fea-
ture of HIV infection [25], and as a result, they demon-
strated that the 28 joint count disease activity score
(DAS-28) ESR overestimates disease activity by as much
as 30 % when compared to DAS28 CRP (Table 1).
Discussion
Therapy of inflammatory arthritis in HIV positive patients
There are potential issues regarding the safety of disease
modifying anti rheumatic drugs (DMARD) and biologic
therapy in HIV positive patients, with most available data
coming from case series. Non-steroidal anti-inflammatory
drugs remain the first line treatment for HIV-associated
arthritis. Due to the typically self-limited nature of the
condition, DMARDS are rarely required [15]. This is in
contrast with the other forms of arthropathy found in as-
sociation with HIV infection. The arthritis of undifferenti-
ated SPA, and indeed all the SPA can improve
significantly with highly active antiretroviral treatment
alone [26]. Both the arthritis and the cutaneous lesions of
HIV-associated reactive arthritis and PsA have been found
to respond to etretinate (0.5–1.0 mg/kg/day) according to
one report [27].
Interestingly, both Indomethacin and hydroxychloro-
quine have demonstrated antiretroviral activity in small
case series [28–30]. The hydroxychloroquine dose used in
one series was 800 mg daily however - a dose not recom-
mended in routine rheumatological practice. Methotrex-
ate was initially viewed as contraindicated in HIV
infection due fears of an increased risk of opportunistic in-
fections [31], but is nowadays used cautiously in HIV posi-
tive RA and PsA patients with higher CD 4 counts
(greater than 100/mm3 [11]), as long as close monitoring
of cell counts is performed [24]. It is still felt though that
it should be avoided in those with concomitant hepatitis C
infection [11]. Sulphasalazine (at a dose of 1–2 g daily)
has been successfully used to treat SPA with no clinical
deterioration in HIV infection [32], and in one reported
case even resulted in an improvement in CD 4 count in a
patient with reactive arthritis [21]. Leflunomide at a dose
of 20 mg daily (used specifically to treat HIV rather than
arthritis) has also been shown to reduce HIV replication
[33]. Mycophenolate (1 g BD) [34], azathioprine [35] and
gold [36] have also been reported to be efficacious in HIV
positive patients with PsA. Short courses of prednisolone
are also considered safe, even in advanced HIV infec-
tion [37]. In one series, Bromocriptine has also been
associated with suppression of acute inflammatory
arthritis in four out of the five patients with reactive
arthritis who failed to respond to sulfasalazine alone.
The exact mechanism of its action in the context is
not well understood [38].
Biologic DMARDS have been used successfully in HIV
positive patients with surprisingly good safety profile. A
series of 8 American HIV positive patients had anti-
Tumour Necrosis Factor (anti-TNF) agents (etanercept,
adalimumab and infliximab) for different rheumatic con-
ditions (two patients with RA, three with PsA, one with
undifferentiated SPA, one with reactive arthritis and one
with ankylosing spondylitis) with good efficacy and no
adverse effects on their HIV disease [39]. The follow-up
in this study was 60 months and the use of the anti-TNF
agents was restricted to those with CD4 cell count more
than 200 cells/ml and viral loads of less than 60 000 cop-
ies/ml at the initiation of the therapy [39]. Clearly, these
patients need screening for latent tuberculosis and vigi-
lant monitoring for the development of tuberculosis.
Most recently, ustekinamab has been used in a patient
with psoriasis and PsA previously refractory to metho-
trexate, adalimumab, etanercept and golimumab. Signifi-
cant improvement was observed in his skin and joint
disease and, after 2 years of therapy, he has maintained a
stable CD 4 count (above 800 mm3) and an undetect-
able viral load while being free of opportunistic infec-
tions [40]. There has been one report however of an
HIV patient with psoriatic arthritis in whom Etanercept
had to be stopped due to recurrent infections [19].
There are several important drug interactions of rele-
vance for HIV positive patients with inflammatory arth-
ritis. For example, ritonavir is a potent inhibitor of liver
enzymes CYP3A4 (which metabolises many commonly
used glucocorticoids) and CYP2D6. Ritonavir can potently
increase the action and duration of action of
Table 1 Summary of clinical characteristics of Inflammatory Articular Syndromes in HIV positive patients (Continued)
Occasional erosions and joint
space narrowing radiographically
ANA, Rheumatoid Factor and HLA
B27 are negative
Sterile, inflammatory synovial fluid
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corticosteroids and severe Cushing’s syndrome has been
reported on several occasions following single intra-
articular injections of triamcinolone (usually as Kenalog)
for musculoskeletal disease [13]. Therefore triamcinolone
preparations should not be administered to patients on
ritonavir.
Conclusions
There are challenges in the management of inflamma-
tory arthritis in patients who are HIV-positive, including
difficulties in the assessment of disease activity and lim-
ited information on the safety of immunosuppressive
drugs in these individuals. Registries for prospective fol-
low up of HIV positive patients with arthropathies are
urgently needed to shed light on clinical features and
natural history of these conditions, and to develop treat-
ment guidelines.
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